Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab monotherapy in moderate to severe atopic dermatitis
NCT03160885Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Jun 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Started Jun 2017; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03160885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03160885.